Wallets are incredibly poor judges of medical efficacy. The FDA rules are in place for very good reasons, namely to prevent snake-oil salesmen and other unscrupulous merchandisers from foisting their -- potentially harmful -- products upon an unsuspecting public.
I would much rather have FDA clearance for medical products and devices than the alternative that you seem to be proposing.
It looks like they do sell this in Europe. Although I'm not sure if that's because it's approved at all, or just because Europe considers it some kind of novelty product rather than a medical device; the FDA and EU categorization of drugs/devices/etc. is a bit different.
"Programmers are quite capable of reviewing the evidence to see if code is effective" — yet, we end up with thousands of people using MongoDB based off fad and hype and losing data by the day.
(Wait, did I just advocate for a government-level code approval board? In the right hands it would probably help if it prevented more Mongos and Hadoops from entering the world.)
Losing your life when you're a layman in the medical field is another.
[1]http://en.wikipedia.org/wiki/Off-label_use [2]http://nielsenhayden.com/makinglight/archives/007140.html There's some important context in the comments.
So are bureaucrats who are subject to the influence of lobbyists. Snake-oil salesmen and peddlers of alternative medicine do sell their stuff under the current system, while true innovation is crushed, as is evident in this case.
There's a number of other offerings that have been made in the same general space, as well.
There is snake oil for sale in every store, and no one has ever been hurt from their test.
There are huge information asymmetries involved when it comes to medical drugs, and also huge barriers to experimenting with different products. "Voting with your wallet" is appropriate for determining which cell phone should be popular, not which medical drugs or medical tests.
We as a society have determined that the appropriate risk versus innovation trade-off when it comes to medicines and drugs is less risk at the potential cost of less innovation. The FDA exists to safeguard that policy.
It's funny that you mention Asia, because the trend in Asian countries is to follow the American/European model. Asians have had enough of thinking "is this rat meat?" every time they bite into a lamb kebob, and are regulating their food and drug industries. And by "asians" I mean the Chinese, because the Japanese and Koreans have adopted the Western regulatory model long ago.
[1] https://en.wikipedia.org/wiki/Capital_offences_in_the_People...
This is what the FDA should be doing. Correcting information asymmetries. With labeling requirements, unbiased PSAs, drug pamphlets and literature. Not telling people what they can and can't put in their bodies, or what businesses can and can't sell on the open market.
In fact, I'd say most government regulatory functions should be set up this way. Clearly inform and educate your citizens, don't opaquely dictate the behavior of your subjects.
For any reasonable requirement, if people/companies don't comply then it has to escalate to [threats of] harsher actions in order to force the reasonable thing to actually happen.
I know you're responding to a more general point, but I don't think any of your post applies to this situation. This is about marketing materials, and more importantly the factual information therein.
If they made that more clear, then they wouldn't have had to send the letter. It's why you see "This is not intended to diagnose, treat, or cure any disease" on all the non-FDA-approved supplements/energy drinks. My money is on them paying the fine and scaling back the marketing.
The purpose behind these FDA rules are to make sure things aren't marketing as "cures" when they aren't. People's health is serious business; there's no room for failure. If 1.0 doesn't work (or makes things worse), then the people that need it might not live to see 1.1.
[1] https://en.wikipedia.org/wiki/Primum_non_nocere [2] https://en.wikipedia.org/wiki/Thalidomide#Birth_defects_cris...
This example is rather famous in the legal world because a) the drug was off-patent for many years before the problems were identified, and so there were many different manufacturers, and b) the problems were often not apparent until decades after exposure had occurred - two factors which make it very difficult to fairly ascribe liability to those who suffered avoidable injuries. This led to some innovative thing in damages/liability allocation which is now an essential part of understanding tort law.
I mention this because I've had some conversations with libertarian legal thinkers where they bring up this same argument of Thalidomide vs. opportunity cost - and its true that the barriers to approval were so low back in the late 50s that it's very unlikely such a drug could ever get on the market these days. Also, the effects were so drastic that that they were quickly noticed, and the number of birth defects ascribable to Thalidomide are in the low 10,000s. By contrast, millions of people are living with the impact of DES, and the magnitude of the affected class is also a factor in the legal significance of the damages formula. So any lawyer who's talking about balancing innovation and regulation in the drug market without addressing DES is being a bit disingenuous, and you should weight your judgment accordingly.
To take the latter point first, drug consumers are generally in a poor position to evaluate the risks of a given medication. If I set up a wheel manufacturing business, and sell square wheels, you are in a poor position to complain about the resulting bumpy ride [1] because the superiority of round wheels is so glaringly obvious. Unless you hold a medical or pharmaceutical degree, though, your ability to evaluate a drug's safety and efficacy is probably very limited. I'm smart enough to read and get the gist of a biochemistry paper to have an idea of what a drug does, but nowhere near knowledgeable enough to review or spot all but the most egregious errors. So while I am the sort of person who reads all the fine print on drug labels and sometimes digs into the academic research, in the end I'm taking a great deal on faith whenever I take medicine. by contrast, the drug manufacturer has not just one biochemical expert, but whole teams of them. This certainly puts them in the best position to foresee and even look for potential problems.
Now back to the first point: drug discovery is not the exact science we'd like it to be due to the gaps in our knowledge. Accordingly, drug companies must be given some leeway, compared to other manufacturers who enjoy a greater degree of foreseeability. suppose I set up a ladder company, but the ladders I manufacture employ such thin metal rungs that they cannot bear any weight above 100 pounds. They look good enough, but soon consumers begin suffering accidents when using them. I could not claim the accidents were unforeseeable since the tensile properties of metals are so well known and the tests are so easy to perform, that I should have realized the risk when designing my product, never mind before shipping it! It would be unfair to hold drug manufacturers to that degree of liability, but on the other hand a) experimental protocols exist precisely to address this problem and are widely understood within the drug industry, and b) since DES was on sale from 1941 onwards and class action lawsuits were brought against manufacturers in the late 1960s, more than enough time had elapsed for industry participants to have apprised themselves of the risk and limited the risk to consumers to a greater extent than they did.
If you read Judge Mosk's opinion, in footnote 24 [2] he summarizes a 7-point test for establishing (rather than allocating) liability. The answer you seek is there:
The suggested requirements are as follows:
1. There existed an insufficient, industry-wide standard of safety as to the manufacture of the product.
2. Plaintiff is not at fault for the absence of evidence identifying the causative agent but, rather, this absence of proof is due to defendant's conduct.
3. A generically similar defective product was manufactured by all the defendants.
4. Plaintiff's injury was caused by this defect.
5. Defendants owed a duty to the class of which plaintiff was a member.
6. There is clear and convincing evidence that plaintiff's injury was caused by a product made by one of the defendants. For example, the joined defendants accounted for a high percentage of such defective products on the market at the time of plaintiff's injury.
7. All defendants were tortfeasors.
This is a very brief abstraction of a key theory in a law review article written by a student at Fordham University, referred to in the opinion as 'the Fordham comment.' This unusually influential article [3] basically sets out a whole theory of 'enterprise liability' and damages allocation addressing why the manufacturers should share liability in the context of the DES in much greater detail, although it's rather painful to read for people who are not legal nerds as it approaches some sort of footnote event horizon. Whether the Sindell court's findings allow the legal academy to be held liable for typographically-induced brain trauma remains unresolved.1. http://dogknobit.com/wp-content/uploads/2013/04/square-wheel...
2. http://online.ceb.com/calcases/C3/26C3d588.htm#SA000885
3. http://ir.lawnet.fordham.edu/cgi/viewcontent.cgi?article=231...
It's difficult to measure how many lives were saved or made substantially more livable because the FDA was not more cautious than it has been. Surely that number is not zero, and perhaps it's greater than the net harm done by drugs whose effects might have been caught by more prolonged testing. I don't think we know.
BTW these are not made up names although they look like it. Google them for a good time if you're bored. I'm more interested in the chemistry issues than the politics or biochemisty, so I'd be more comfortable (authoritative?) talking about the location of the methyl groups than liver toxicity, but my first paragraph has no known intentional errors (although it probably has some unintentional errors LOL).
I guess the point of this ramble is if a company exists to provide highly personalized customized services, then using a metric of "joe average" is probably not overly meaningful. The response of joe average to a disease percentage is maybe not relevant to the response of someone with a high percentage to the same result.
We have a pretty good medical system designed for joe average, and its intersection with radically personalized services is unsurprisingly going to be an epic disaster.
A whole lot of people have died from contaminated blood transfusions: http://articles.latimes.com/1994-08-31/news/mn-33183_1_aids-...
That's another case of a medical intervention ending up doing more harm than good.
I would guess you're asking to google for list of withdrawn drugs which lead me to
http://en.wikipedia.org/wiki/List_of_withdrawn_drugs
Another interesting side effect is most mass shooters were on anti-depressants, although that's probably not the kind of direct fatal side effect you're looking for. Its a challenging google game to track down the toxicology reports for each mass shooter weeks after the smoke clears and identify which anti-depressant they were on at the time. Sometimes its a different kind of med, sometimes they're not on any med at all, although thats kind of rare.
That one is easy: don't fast track drugs that are only marginally better than their peers, if at all, because by definition they aren't as important.
I don't have as clear an answer for pregnancy, other than exempting pregnant users from the fast track approval, but I'm not sure how a slower process actually protects pregnancies in the first place.
I'm moderately on the side of government not interfering where possible. But medicine and medical devices is one area in which such interference is quite likely a positive influence, on the whole.
Fact is, we don't want a return to the era of patent medicines. For every user of 23andme who is well-informed enough to know that the information is not reliable, experience shows that there will be another who is not. And these people will base life- and health-affecting decisions on the results provided by unregulated products. Then maybe they'll get sick or die.
That's why there are regulatory standards for medical devices and services. These standards don't prevent the sale of 23andme's services, but require that they are either a) regulated and proven to work, or b) explicitly and clearly described as not being so.
Yes, there are rampant inefficiencies within this system. But I'd wager that it's probably better than the alternative.
The funny thing here, is that barring lab errors, which I think are highly unlikely unless they are being incredibly shoddy, which would take effort, the information that 23andMe provides is very reliable. Now it is debatable as to whether the individual's interpretation is (for example in the Alcohol Dehydrogenase gene, many, many, many caucasian users don't bother to read that the test is only informative for asians, but it's definitely there, in bold letters, etc.)
Could you explain a scenario where basing life and health decisions on 23andMe's product could lead to sickness and death? Maybe it's "because I'm sophisticated", but this biochemist can't really see that happening.
That's the point of certification - is the process reliable? Are the warnings clear? I won't cast any aspersions on the product (because it's pretty awesome), but I do see these as risks and requirements.
Could you explain a scenario where basing life and health decisions on 23andMe's product could lead to sickness and death?
"I've got all these symptoms of diabetes. But 23andme said I had a low risk! It's probably nothing. Guess I'll eat another pie."
If 23andme has shoddy lab practices, or unclear explanation of the limitation of their testing, then that's a risk. The process of certification involves managing that risk.
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001877....
(this study is about mammograms of healthy women, another example of a health screening tool)
We found that breast cancer mortality was an unreliable outcome that was biased in favour of screening, mainly because of differential misclassification of cause of death. The trials with adequate randomisation did not find an effect of screening on cancer mortality, including breast cancer, after 10 years (RR 1.02, 95% CI 0.95 to 1.10) or on all-cause mortality after 13 years (RR 0.99, 95% CI 0.95 to 1.03).
Numbers of lumpectomies and mastectomies were significantly larger in the screened groups (RR 1.31, 95% CI 1.22 to 1.42) for the two adequately randomised trials that measured this outcome; the use of radiotherapy was similarly increased.
So women who get more screening get more treatment but didn't live longer (unnecessary treatment)
Study continues:
This means that for every 2000 women invited for screening throughout 10 years, one will have her life prolonged and 10 healthy women, who would not have been diagnosed if there had not been screening, will be treated unnecessarily. Furthermore, more than 200 women will experience important psychological distress for many months because of false positive findings. It is thus not clear whether screening does more good than harm. To help ensure that the women are fully informed of both benefits and harms before they decide whether or not to attend screening, we have written an evidence-based leaflet for lay people that is available in several languages on www.cochrane.dk.
A mammogram is a screening test. 23andMe is another type of screening test. You aren't getting extra mammograms because of 23andMe, they are the same thing.
Mammogram can screen you for early detection of a serious disease. 23andMe can do the same (they advertise - this is what the FDA has a problem with).
More screening for all diseases doesn't mean better outcome, and can be harmful, depending on the test, the people screened, the disease, etc., etc. and can lead to more disease (needless treatment). Throwing more screening at the wall for every disease doesn't do more good all the time. Especially when we learn that some diseases (prostate cancer) cause no symptoms most of the time. Treating these asymptomatic prostate cancers is very harmful, because they are harmless unless they progress. The treatment is risky and has serious side effects (impotence!)
Every time we have a screening test, we have to look at the science. What are we screening for? What is the good? What is the bad? Who is helped? Who is harmed? Do the positives outweigh the negatives?
Another outdated screening tool is the breast self exam - it was found (in scientific studies) it didn't do any good and caused harm (http://en.wikipedia.org/wiki/Breast_self-examination) Lots of over treatment without a reduce in cancer rates. Also, just learning about it increases women's worry and anxiety about breast cancer. This is a harmful screening tool. This was studied and abandoned.
----
BRCA test has nothing to do with this example.
Mammograms are currently very common in women a certain age >40 or >50. Most women get them every few years as part of their health maintenance to check for the presence of cancer, tumors or lumps. Right now there is research coming out that is questioning that practice, but the practice hasn't caught up to the research and most doctors say "get your mammogram" without informing patients of the risks, they treat it like it is "all good." That was the point of this research to ask "are we doing the right thing here by screening all these healthy women with mammograms? Let's study that."
I will personally opt out of the mammogram hype when I reach the mammogram age. I'm also going to inform my mother of the current research on the matter, I know she's already had a few mammograms herself.
Certainly, there is science to support certain claims of the class made in the reports 23andMe provides being made with some degree of reliability based on the kind of inputs 23andMe takes in. Whether what 23andMe actually does from end-to-end makes the actual reports they provide reliable in real world condition is...well, exactly the question they have seem to have decided not to expend the effort to answer even after initiating the process of getting clearance from the FDA to market their diagnostic product.
I'm with you. I'd much prefer a bunch of people die first so the rest of us can "vote with our wallets" instead of having a government agency step in and try to fix things before anyone gets hurt. I mean, my start-up is going to sell baby food laced with arsenic because I once heard that arsenic makes babies smarter and I think I once ingested some accidentally and I didn't die. If it really does end up killing babies, well, the market will eventually correct itself. And no harm, no foul, man. Except the dead babies. But at least I wouldn't have some nebbish bureaucrat knocking at my door trying to tell this American how to live his life.
Liability for defective (whether through malice, negligence, or in some cases on a strict liability basis) products is government intervention in the marketplace, and is specifically designed to address one of the ways that reality does not align with the presuppositions under which an unregulated "free market" is ideal, to wit, that people generally do not, in fact, act with perfect knowledge of the outcomes of economic decisions when they engage in them.
It is no different than many other government interventions in the marketplace in its basis.
> And also, the FDA is not some magic fairy dust that will shield you from bad products. Mountain Dew still has BVO in it, for example.
That does not mean that its approval procedures (and procedures for reviewing products already on the market) do not have utility in providing clearer information on products within its regulatory domain and helping consumers avoid bad products.
There have been a bunch of concerns in this thread that are valid -- e.g., people might have to deal with bad news, or may see false positives, etc., that could cause them some inconvenience (though I would argue that 23andMe doesn't tell you that you have cancer, just maybe whether or not you're likely to).
Regardless, the idea that I could die from a 23andMe test is about as far-fetched as one can get.
You have unwittingly affirmed the very argument you are attempting to refute. Their inability to make accurate functional predictions from genomic data has much less to do with the technology (sequence vs. array) than it does with the fact that, isolated instances aside, nobody knows how to do this well. I am a 23andMe user myself and, knowing a bit about statistical genomics, I was surprised how credulously the results of one or two GWAS papers are presented as an almost-diagnosis on their website. GWAS are plagued by all sorts of confounding issues and the statistical evidence in favor of their conclusions is often extremely weak. This is not something that the general public appreciates, so I can see why FDA might get involved.
So actually you can't buy elixir sulfanimide anymore. Because it was poisonous. It resulted in more than 100 deaths in 1937. This was before the FD&C Act, requiring safety tests. The founder of Massengill refused to take responsibility for the results: "We have been supplying a legitimate professional demand and not once could have foreseen the unlooked-for results. I do not feel that there was any responsibility on our part." It should be noted that there was a sulfanimide craze on at the time, as the first commercial antibiotic, so there was much money to be made.
One woman wrote to President Roosevelt, about her dead daughter: "The first time I ever had occasion to call in a doctor for [Joan] and she was given Elixir of Sulfanilamide. All that is left to us is the caring for her little grave. Even the memory of her is mixed with sorrow for we can see her little body tossing to and fro and hear that little voice screaming with pain and it seems as though it would drive me insane. ... It is my plea that you will take steps to prevent such sales of drugs that will take little lives and leave such suffering behind and such a bleak outlook on the future as I have tonight."
Source: http://en.wikipedia.org/wiki/Elixir_sulfanilamide
Massengill paid a minimum fine and continued on until it was acquired in 1971.
I don't mind that we have set up an agency to make sure that medical products and devices are safe to use and do what they say they are going to do. It's far more efficient than having to do it individually. And there's always, evidently, people who won't, because they trust their doctor or the brand. And, being medical products and devices, sometimes those people or their loved ones die.
Look how smallpox vaccine was discovered. Edward Jenner inoculated a young boy with cow pox, then attempted to infect him with smallpox a dozen times. Obviously we can't go around convincing young children to take infectious doses of deadly viruses. But we also cant send FDA thugs after every Silicon Valley startup pushing the boundaries of genomics research. So where do we draw the line?
But in this specific case, seems FDA isn't being totally unreasonable. For example, from the letter
"Thus, months after you submitted your 510(k)s and more than 5 years after you began marketing, you still had not completed some of the studies and had not even started other studies necessary to support a marketing submission for the PGS"
seems like a good idea to require companies to do this
So either the government ensures the above or it does not get accomplished? There are no third parties that could take this on? I find that hard to believe.
In fact, I would venture they are worse because they have to be paid somehow, and if they are paid by industry, you are ripe for regulatory capture. It can be difficult to get consumers to pay for it unless you include some kind of tax in the product they buy in which case you've arrived at a pseudo-government agency.
You might be able to find countries where regulation is less strict or non-existent but I'd imagine that people's trust in medicine in said countries is less than in the regulated ones (as you most certainly would have rouge players abusing the lack of regulation).
edit: Added last sentence in 1st paragraph
Yet their adverting makes it sound like it is. Specifically talking about how it can be used find un-diagnosed disease and health problems.
Copy and paste and argument from the internet if you can't form one on your own. Don't pretend "herp derp Rand Paul" is valid.
The gov wants to decide what's best for the people. Should the people decide differently, using their wallets for example, this anomaly will be quashed.
This trend is especially strong in the medical field - gov approval required everywhere, then people wonder why medical things are so damn expansive.
I use 23andme and I'm happy with the information provided. I know it's not reliable - it's not a lab test anyone will use to base important decisions on, since it is not a full sequence of genes.
Yet, by being commercially available and easy to use, it is paving the way for commercial offers of full genome sequencing, which I damn well intend to use when they reach the $500 threshold.
However, gov actions like this one may very well make that impossible, making sure the only full genome sequencing offers there will be will be "FDA cleared" at a huge markup.
Suggestions to "medical" like companies - get out the gov eye. Move your business to Asia, the caribbean or wherever the gov will not get in your way like this. I want to keep using (and recommending) your products!